Australian Pharmaceutical Industries
FollowAustralian Pharmaceutical Industries Archives
Sprout Organic locks new distribution deal with API
Sprout Ogranic’s products will now be stocked across Soul Pattinson and Priceline Pharmacies.
ACCC clears the way for Wesfarmers to acquire Priceline parent
In talking with stakeholders, the ACCC found few concerns about potential market disruption because there are a large nu...
ACCC clears the way for Wesfarmers to acquire Priceline parent
In talking with stakeholders, the ACCC found few concerns about potential market disruption because there are a large nu...
Woolworths pulls bid to pick up pharmacy group API
Woolworths said it was unable to validate the financial returns it would require from the acquisition after completing i...
“We are not here to disrupt the sector”: Woolies’ case to pharmacists
Woolies chief executive Brad Banducci has penned an open letter to Australian pharmacists outlining the supermarket grou...
Wesfarmers moves to block Woolies’ bid for API
According to Wesfarmers, a growing number of pharmacists and chemists find the overlap between Woolworths’ products and ...
Woolies blocks Wesfarmers’ plans for API with $872 million bid
According to Woolworths, API’s board has determined their proposal is likely to be superior to Wesfarmers’, and it is wo...
Rival pharmaceutical company seeks to keep API from Wesfarmers
Sigma Healthcare looks to sweep up its rival before Wesfarmers can create its new division.
Wesfarmers makes revised bid for Priceline-owner
API's board is recommending shareholders back the revised offer, which will now see them paid out at a 37 per cent premi...
API commits to major NSW distribution centre
Australian Pharmaceutical Industries will construct a new 32,506sqm NSW distribution centre at Marsden Park to improve i...
Priceline benefits from timely e-commerce launch
Demand for Priceline's Click & Collect and Click & Deliver soars during the pandemic.
Priceline Pharmacy sales lift 2.4 per cent to $2.2 billion
API reports $4.0 billion in revenue for FY19 as flagship health and beauty retailer sees like-for-like sales return to g...
API banks on its own “growth engines” after Sigma merger taken off the table
CEO Richard Vincent said API is no rush to sell its Sigma shares.
API offers $727m for Sigma Healthcare
Drug distributor plans to buy its rival in the face of increased competitive and regulatory pressures.
API flags profit lift
Australian Pharmaceutical Industries expects to lift underlying profit despite a tough retail environment.
